Cachet Pharmaceutical Co Ltd (002462) - Net Assets
Based on the latest financial reports, Cachet Pharmaceutical Co Ltd (002462) has net assets worth CN¥5.90 Billion CNY (≈ $864.00 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.93 Billion ≈ $1.75 Billion USD) and total liabilities (CN¥6.02 Billion ≈ $881.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cachet Pharmaceutical Co Ltd (002462) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.90 Billion |
| % of Total Assets | 49.5% |
| Annual Growth Rate | 13.76% |
| 5-Year Change | 3.88% |
| 10-Year Change | 100.18% |
| Growth Volatility | 20.81 |
Cachet Pharmaceutical Co Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Cachet Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Cachet Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cachet Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual net assets of Cachet Pharmaceutical Co Ltd from 2007 to 2025. For live valuation and market cap data, see 002462 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.88 Billion ≈ $859.82 Million |
-3.12% |
| 2024-12-31 | CN¥6.06 Billion ≈ $887.48 Million |
-0.44% |
| 2023-12-31 | CN¥6.09 Billion ≈ $891.38 Million |
+2.87% |
| 2022-12-31 | CN¥5.92 Billion ≈ $866.52 Million |
+4.69% |
| 2021-12-31 | CN¥5.66 Billion ≈ $827.73 Million |
+6.25% |
| 2020-12-31 | CN¥5.32 Billion ≈ $779.07 Million |
+8.15% |
| 2019-12-31 | CN¥4.92 Billion ≈ $720.37 Million |
+31.88% |
| 2018-12-31 | CN¥3.73 Billion ≈ $546.21 Million |
+16.75% |
| 2017-12-31 | CN¥3.20 Billion ≈ $467.85 Million |
+8.92% |
| 2016-12-31 | CN¥2.94 Billion ≈ $429.52 Million |
+33.30% |
| 2015-12-31 | CN¥2.20 Billion ≈ $322.23 Million |
+31.50% |
| 2014-12-31 | CN¥1.67 Billion ≈ $245.05 Million |
+28.48% |
| 2013-12-31 | CN¥1.30 Billion ≈ $190.72 Million |
+15.59% |
| 2012-12-31 | CN¥1.13 Billion ≈ $165.01 Million |
+3.42% |
| 2011-12-31 | CN¥1.09 Billion ≈ $159.55 Million |
+6.41% |
| 2010-12-31 | CN¥1.02 Billion ≈ $149.95 Million |
+81.71% |
| 2009-12-31 | CN¥563.92 Million ≈ $82.52 Million |
+18.71% |
| 2008-12-31 | CN¥475.03 Million ≈ $69.51 Million |
-17.74% |
| 2007-12-31 | CN¥577.44 Million ≈ $84.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cachet Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1163.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.54 Billion | 58.38% |
| Common Stock | CN¥291.71 Million | 6.70% |
| Other Comprehensive Income | CN¥241.31 Million | 5.55% |
| Other Components | CN¥1.28 Billion | 29.37% |
| Total Equity | CN¥4.35 Billion | 100.00% |
Cachet Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Cachet Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sable Offshore Corp.
NYSE:SOC
|
$586.10 Million |
|
ENCE Energía y Celulosa S.A
MC:ENC
|
$586.18 Million |
|
Zhejiang Jihua Group Co Ltd
SHG:603980
|
$586.33 Million |
|
Beijing Jingpin Tezhuang Technology Co. Ltd. A
SHG:688084
|
$586.34 Million |
|
Hubei Biocause Heilen Pharmaceutical Co. Ltd.
SHE:301211
|
$586.03 Million |
|
Log-In Logística Intermodal S.A
SA:LOGN3
|
$585.98 Million |
|
Movado Group Inc
NYSE:MOV
|
$585.76 Million |
|
Hartadinata Abadi Tbk PT
JK:HRTA
|
$585.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cachet Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,326,637,737 to 4,351,804,983, a change of 25,167,246 (0.6%).
- Net income of 111,378,719 contributed positively to equity growth.
- Dividend payments of 108,868,996 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥111.38 Million | +2.56% |
| Dividends Paid | CN¥108.87 Million | -2.5% |
| Other Changes | CN¥22.66 Million | +0.52% |
| Total Change | CN¥- | 0.58% |
Book Value vs Market Value Analysis
This analysis compares Cachet Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.92x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.39x to 0.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥3.13 | CN¥13.73 | x |
| 2008-12-31 | CN¥2.59 | CN¥13.73 | x |
| 2009-12-31 | CN¥3.09 | CN¥13.73 | x |
| 2010-12-31 | CN¥5.05 | CN¥13.73 | x |
| 2011-12-31 | CN¥4.49 | CN¥13.73 | x |
| 2012-12-31 | CN¥4.56 | CN¥13.73 | x |
| 2013-12-31 | CN¥4.92 | CN¥13.73 | x |
| 2014-12-31 | CN¥5.36 | CN¥13.73 | x |
| 2015-12-31 | CN¥5.96 | CN¥13.73 | x |
| 2016-12-31 | CN¥7.90 | CN¥13.73 | x |
| 2017-12-31 | CN¥8.79 | CN¥13.73 | x |
| 2018-12-31 | CN¥9.98 | CN¥13.73 | x |
| 2019-12-31 | CN¥13.12 | CN¥13.73 | x |
| 2020-12-31 | CN¥12.46 | CN¥13.73 | x |
| 2021-12-31 | CN¥13.29 | CN¥13.73 | x |
| 2022-12-31 | CN¥14.01 | CN¥13.73 | x |
| 2023-12-31 | CN¥14.58 | CN¥13.73 | x |
| 2024-12-31 | CN¥14.81 | CN¥13.73 | x |
| 2025-12-31 | CN¥14.85 | CN¥13.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cachet Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.57%
- • Asset Turnover: 1.53x
- • Equity Multiplier: 2.93x
- Recent ROE (2.56%) is below the historical average (10.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 32.37% | 27.55% | 0.77x | 1.52x | CN¥126.20 Million |
| 2008 | 8.75% | 4.28% | 1.31x | 1.55x | CN¥-5.92 Million |
| 2009 | 7.55% | 3.74% | 1.24x | 1.63x | CN¥-13.74 Million |
| 2010 | 4.75% | 3.62% | 0.94x | 1.40x | CN¥-53.65 Million |
| 2011 | 6.01% | 3.54% | 1.14x | 1.49x | CN¥-42.21 Million |
| 2012 | 5.96% | 2.55% | 1.33x | 1.75x | CN¥-44.23 Million |
| 2013 | 10.97% | 3.67% | 1.27x | 2.35x | CN¥11.49 Million |
| 2014 | 17.72% | 4.09% | 1.23x | 3.53x | CN¥99.34 Million |
| 2015 | 12.08% | 2.11% | 1.39x | 4.11x | CN¥29.84 Million |
| 2016 | 11.26% | 2.03% | 1.49x | 3.72x | CN¥24.99 Million |
| 2017 | 11.94% | 1.85% | 1.55x | 4.17x | CN¥42.92 Million |
| 2018 | 13.12% | 1.82% | 1.66x | 4.34x | CN¥77.91 Million |
| 2019 | 10.98% | 1.69% | 1.70x | 3.81x | CN¥33.40 Million |
| 2020 | 8.75% | 1.37% | 1.65x | 3.89x | CN¥-45.31 Million |
| 2021 | 9.11% | 1.38% | 1.72x | 3.84x | CN¥-34.78 Million |
| 2022 | 7.28% | 1.13% | 1.58x | 4.06x | CN¥-110.87 Million |
| 2023 | 5.90% | 0.83% | 1.75x | 4.04x | CN¥-173.99 Million |
| 2024 | 3.71% | 0.67% | 1.71x | 3.24x | CN¥-272.00 Million |
| 2025 | 2.56% | 0.57% | 1.53x | 2.93x | CN¥-323.80 Million |
Industry Comparison
This section compares Cachet Pharmaceutical Co Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,736,488,143
- Average return on equity (ROE) among peers: 6.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cachet Pharmaceutical Co Ltd (002462) | CN¥5.90 Billion | 32.37% | 1.02x | $586.08 Million |
| Yunnan Hongxiang Yixintang (002727) | $2.08 Billion | 14.28% | 0.41x | $962.32 Million |
| Luyan Pharma Co Ltd (002788) | $2.56 Billion | 11.95% | 2.90x | $642.43 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-1.50 Billion | 0.00% | 0.00x | $20.47 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $1.33 Billion | 8.38% | 0.84x | $791.18 Million |
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | $1.59 Billion | -15.22% | 2.98x | $287.04 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $2.16 Billion | 8.85% | 1.54x | $921.91 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $749.32 Million | 9.15% | 0.86x | $324.81 Million |
| Dashenlin Pharm Grp Co Ltd (603233) | $8.66 Billion | 14.26% | 2.06x | $2.78 Billion |
| Laobaixing Pharmacy (603883) | $7.00 Billion | 5.46% | 1.84x | $1.35 Billion |
About Cachet Pharmaceutical Co Ltd
Cachet Pharmaceutical Co., Ltd. engages in the wholesale, retail, and logistics of pharmaceutical products in China. The company also offers medical drugs, medical devices, e-commerce products, and warehousing logistics services. It sells its products through online and offline channels. The company was founded in 1997 and is headquartered in Beijing, China.